WALTHAM,
Mass., Oct. 30,
2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:
SYRE), a clinical-stage biotechnology company utilizing
best-in-class antibody engineering, rational therapeutic
combinations, and precision medicine approaches to target improved
efficacy and convenience in the treatment of Inflammatory Bowel
Disease ("IBD"), today announced that management will participate
in the following upcoming investor conferences:
Event: Guggenheim's Inaugural Healthcare Innovation
Conference
Date: Wednesday,
November 13, 2024
Time: 2:30pm ET
Event: Stifel 2024 Healthcare Conference
Date:
Monday, November 18, 2024
Time: 1:15 pm ET
Event: Jefferies London Healthcare
Conference
Date: Wednesday,
November 20, 2024
Time: 10:30 am GMT
Live audio webcasts and replays of these events will be
available on the Spyre investor events website at
https://ir.spyre.com/events-and-presentations.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company
that aims to create next-generation inflammatory bowel disease
(IBD) products by combining best-in-class antibody engineering,
rational therapeutic combinations, and precision medicine
approaches. Spyre's pipeline includes extended half-life antibodies
targeting α4β7, TL1A, and IL-23. For more information, visit
Spyre's website at www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and
LinkedIn
View original content to download
multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-upcoming-november-investor-conferences-302291439.html
SOURCE Spyre Therapeutics, Inc.